z-logo
open-access-imgOpen Access
NIH 3 T 3 cells overexpressing CD 98 heavy chain resist early G 1 arrest and apoptosis induced by serum starvation
Author(s) -
Hara Kaori,
Ueda Shiho,
Ohno Yoshiya,
Tanaka Toshiyuki,
Yagi Hideki,
Okazaki Shogo,
Kawahara Rieko,
Masayuki Takechi,
Enomoto Takemi,
Hashimoto Yoshiyuki,
Masuko Kazue,
Masuko Takashi
Publication year - 2012
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2012.02304.x
Subject(s) - apoptosis , starvation , chemistry , microbiology and biotechnology , biology , biochemistry , endocrinology
C D 98 is a heterodimeric glycoprotein of 125‐ kD a, which consists of a 90‐ kD a heavy chain (hc) subunit and 35‐ kD a to 55‐ kD a light chain (lc) subunits. It is strongly expressed on the surface of proliferating normal cells and almost all tumor cells. To investigate the participation of CD 98 in cellular proliferation and malignant transformation, we analyzed cell‐cycle progression of NIH 3T3 clones transfected with cDNA of human CD 98hc. Although NIH 3T3 and control transfectant cells grown to the subconfluent state were arrested in the G 0/ G 1 phase by serum starvation, considerable portions of CD 98hc‐transfected cells resided at S and G 2/ M phases. Under serum‐starved and confluent conditions, significant fractions (20–25%) of NIH 3 T 3 and control transfectant cells contained less than 2n content DNA , indicating occurrence of apoptosis, whereas no apoptotic cells were detected in CD 98hc‐transfectant cells. Under serum‐starved conditions, a marked increase in the levels of cyclin D 1 and cyclin E and a decrease in p16 were observed in CD 98hc‐transfectant cells. The reverse was true for NIH 3 T 3 and control transfectant cells. Our results suggest that resistance to G 1 arrest and apoptosis by CD 98 overexpression are associated with high G 1‐cyclins and low p16 levels. ( Cancer Sci , doi: 10.1111/j.1349‐7006.2012.02304.x, 2012)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here